TrialAlimentary pharmacology & therapeutics2019

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.

Kin Seng Liem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.